Announcements, press, and milestones.

One point anchored the discussion: innovation only matters to patients if it can actually reach them. Regulatory alignment, cross-border capital, and clinical data that travels across borders matter just as much as the science itself.

Hong Kong’s position was a focal point of the conversation — deep capital markets, proximity to the Greater Bay Area’s manufacturing and R&D base, and long-standing relationships with regulators across Asia-Pacific. That combination makes Hong Kong more than a financing hub: it is a credible bridge between Chinese innovation and the global patients who need it.

The panelists shared views on what it will actually take to build that trust: harmonized standards, more cross-border trial collaboration, and a shared commitment to patient outcomes.

We thank the panelists and BIOHK2026 for a candid conversation, and look forward to continuing it.

#BIOHK2026 #Biotech #HongKong #AsiaPacific #HealthcareInnovation #VentureCapital

The discussion covered how portfolio companies can navigate Asia’s capital ecosystem — from the nuances of markets across different hubs to what it takes to build credible, repeatable, and sustainable growth stories. Paul shared perspectives on the importance of global-mindedness, financial discipline, depth of value creation, strong corporate governance, and team readiness in creating meaningful outcomes for investors, regulators, patients and customers.

Moderator Anastasia Miros (CFGI) led the panel alongside Andrew Ng (VMS Group), Kenneth Sun (Royalty Pharma), and Jean-Baptiste Roy (Seveno Capital).

We thank MedTech World and our fellow panelists for a candid discussion on navigating the journey from Series A to IPO in Asia.

#MedTechWorld #MedTech #CapitalMarkets #VentureCapital #IPO #Asia #LifeSciences #Healthcare #Innovation

Mingyu noted that “AI is fundamentally a compressed ensemble of human knowledge” and shared how AI alone is not enough in a field as complex and data-constrained as life sciences.

The future lies in human-AI collaboration, combining scientific judgment with computational power. We believe AI will increasingly permeate the entire drug development process, transforming how therapies are discovered, translated, and delivered, while raising the quality and speed of innovation across the industry.

#AIDrugDiscovery #Biotech #ArtificialIntelligence #LifeSciences #DrugDevelopment #AIinHealthcare #PrecisionMedicine #HumanAICollaboration #BiotechInnovation #FutureOfMedicine

We are delighted to welcome Ethan Than to Aulis as Venture Partner. Ethan brings extensive experience as a biopharma operator and dealmaker, spanning drug development, strategic transactions, business development, and AI-enabled innovation. At Aulis, Ethan will work with our investment team, founders, and portfolio companies, bringing an operator’s and dealmaker’s perspective across investment evaluation, company building, and strategic growth.

The discussion covered three critical themes:

What defines a successful in-China strategy for health and life sciences MNCs in today’s rapidly shifting landscape.

How Chinese innovation is reshaping global R&D — and what companies need to do to keep pace or catch up.

Where Europe fits between the US and China, and its increasingly advantageous positioning in the global life sciences order.

These questions go to the heart of the opportunity — and the complexity — facing anyone operating at the intersection of global health and China’s innovation engine. We’re proud to have Franck’s perspective informing our work across the portfolio.

The full episode (video, audio and transcript) is available now: https://www.chinahealthpulse.com/p/the-china-decision-room-what-global

#Biotech #Biopharma #LifeSciences #GlobalHealth #VentureCapital #Innovation

Aulis Capital was represented at LEAP EAST Panel. Our founding Managing Partner spoke on the “From Lab to Unicorn: Building a Biotech Success Story in Asia” panel at LEAP East.

The conversation explored what it really takes to move breakthrough science out of the lab and into companies built to scale, from navigating regulatory pathways across Asian markets to building the right teams and securing capital at each stage of growth. Asia’s biotech ecosystem is maturing quickly, with strong momentum behind founders who can pair deep scientific expertise with sharp commercial execution.

We thank Michael Rinaman and Jia Zhuang for a thoughtful discussion, and to everyone who stopped by afterward to chat. Conversations like these are exactly why events like LEAP East matter, pushing the whole ecosystem forward.

Exciting times ahead for the next wave of Asian biotech innovation.

#LEAPEast #Biotech #LifeSciences #Asia #Innovation

Aulis was represented at BIO 2026, where Nisa joined a panel on cross-border biotech partnerships amid a shifting market — drawing a full room and overflow attendance. The discussion underscored that capital is recalibrating rather than retreating, with sustained appetite for scientifically differentiated assets. We thank co-panelists Lila Hope and Ken Song, and moderator June Lee, for the discussion. We look forward to Philadelphia in 2027.

#CrossBorderPartnerships #BiotechInvesting #GlobalHealth #Pharma #VentureCapital

We were pleased to have our Venture Partner, Paul Li, serve on the judging panel at the HKMA Global Innovation Day and the HKMA / HKT Global Innovation Award 2025/26, held at the Hong Kong Convention and Exhibition Centre.

The talent and ideas showcased were truly inspiring, highlighting how Hong Kong innovators are driving progress across key sectors including AI, sustainability, and fintech.

Thank you to HKMA for the invitation, and congratulations to all finalists. We look forward to seeing these ideas come to life.

#Innovation #Startups #Entrepreneurship #VentureCapital #TechInnovation #AI #FinTech #Sustainability #FutureOfWork #HKMA #GlobalInnovation #InnovationEcosystem

Last week, Aulis Capital CFO Grace Ng and Venture Partner Alwin Poon designed and led a Hong Kong immersion programme for 12 master’s students from Columbia University’s School of International and Public Affairs (SIPA) and Columbia Engineering (SEAS) — part of Aulis Capital’s ongoing commitment to bridging global talent with Asia’s innovation frontier.

The cohort was incredibly diverse — MPA, MIA, and MA Energy & Finance candidates drawn from eight countries and cultural backgrounds, spanning serving policymakers and civil servants, scientists and researchers, investment bankers, VC and PE professionals, and founders. Exactly the kind of room where a single conversation can travel.

The day began with a visit to the HKUST Business School — consistently ranked among the world’s top business schools and a cornerstone of Asia’s research and innovation ecosystem — and the Hong Kong Generative AI Research and Development Centre (HKGAI) at HKUST, one of HK’s most significant initiatives on frontier AI infrastructure.

Grace and Alwin engaged the group on where technology development in Asia is heading: the pace of AI deployment with a healthcare focus, and how Hong Kong’s unique position — a bridge between East and West — shapes capital and innovation flows across borders.

That’s the kind of exchange worth crossing an ocean for.

#HKUST #ColumbiaUniversity #Innovation #Aulis #GlobalTalent #AsiaInnovation #HealthcareInvestment

Our Founding Managing Partner Nisa Leung joined the “China Going Global: Next Chapter for Capital Markets” panel at the J.P. Morgan Global China Summit in Shanghai last Friday.

Nisa was joined on the panel by Bonnie Y Chan, CEO of Hong Kong Exchanges and Clearing, with Anu Aiyengar, J.P. Morgan’s Global Head of Advisory and M&A, moderating.

Healthcare innovation remains a defining part of China’s globalization story. The discussion explored the next phase of China’s integration with global capital markets, and the opportunities ahead for companies and investors alike.

#GlobalChinaSummit #CapitalMarkets #ChinaGoingGlobal #JPMorgan #HKEX #Aulis